Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gord Adamson"'
Publikováno v:
Bioconjugate Chemistry. 17:530-537
A novel conjugate of human hemoglobin (Hb) and the nucleoside analogue ribavirin (RBV) was synthesized to demonstrate the utility of Hb as a biocompatible drug carrier for improved drug delivery in the treatment of liver disease. RBV is used in combi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9295543c6ca43186ed08c7f2ad4f6c7
https://doi.org/10.1021/bc0503317
https://doi.org/10.1021/bc0503317
Publikováno v:
Cancer Research. 76:2055-2055
Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide; few treatment options are available, especially for advanced stage disease. Therapure has developed a novel drug delivery platform based upon the attachmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f491f146940a1d5c2da7f63212cfb94b
https://doi.org/10.1158/1538-7445.am2016-2055
https://doi.org/10.1158/1538-7445.am2016-2055
Publikováno v:
Journal of Clinical Oncology. 34:e14061-e14061
e14061Background: Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide. Current standard of care provides only a modest improvement in overall survival and ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fb3b917f61495748b9b8b371aa6983c
https://doi.org/10.1200/jco.2016.34.15_suppl.e14061
https://doi.org/10.1200/jco.2016.34.15_suppl.e14061
Autor:
Gord Adamson, Peter C.W. Kim, Thomas Engelhardt, Tal Shichor, Mark W. Crawford, David Bell, F. J. Lou Carmichael
Publikováno v:
Anesthesiology. 107(2)
Background Erythrocyte transfusion decreases morbidity in sickle cell disease, but is not without risk. Use of a hemoglobin-based oxygen carrier could offer the benefits of erythrocyte transfusion while reducing related complications. The authors tes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e5018f519963210a683e695fd5bc64a
https://pubmed.ncbi.nlm.nih.gov/17667573
https://pubmed.ncbi.nlm.nih.gov/17667573
Autor:
Pieter Biessels, David S. Bell, M. James Phillips, Nancy Ng, Laisum Fung, Ian D. McGilvray, Gord Adamson, Caroline Woods, Reginald M. Gorczynski, Louise A. Scrocchi, Max Ma, Adam Levy, Cheryl Koscik, William He, Steve Brookes, Andrea Rowe, Gary A. Levy, Anand Ghanekar
Publikováno v:
Hepatology (Baltimore, Md.)
Side effects of interferon–ribavirin combination therapy limit the sustained viral response achievable in hepatitis C virus (HCV) patients. Coupling ribavirin to macromolecular carriers that target the drug to the liver would reduce systemic compli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eaef32cfe480d5985dd067fdfcec5d3
https://pubmed.ncbi.nlm.nih.gov/16496340
https://pubmed.ncbi.nlm.nih.gov/16496340